4,130 Shares in Alnylam Pharmaceuticals, Inc. (ALNY) Purchased by M&T Bank Corp

M&T Bank Corp acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,130 shares of the biopharmaceutical company’s stock, valued at approximately $331,000.

A number of other hedge funds have also recently modified their holdings of the business. Pacer Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 22.0% during the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 2,093 shares during the period. Hemenway Trust Co LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $235,000. BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after acquiring an additional 4,732,617 shares during the period. Federated Investors Inc. PA grew its position in shares of Alnylam Pharmaceuticals by 522.9% during the 2nd quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock valued at $4,968,000 after acquiring an additional 52,293 shares during the period. Finally, Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $320,000. 94.25% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/12/4130-shares-in-alnylam-pharmaceuticals-inc-alny-purchased-by-mt-bank-corp.html.

A number of research firms have recently weighed in on ALNY. Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $62.00 to $163.00 in a research report on Monday, October 2nd. Chardan Capital reissued a “buy” rating and set a $124.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, September 25th. Jefferies Group LLC increased their target price on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, September 26th. Stifel Nicolaus reissued a “hold” rating and set a $83.00 target price (up from $56.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $116.00 target price (up from $110.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 20th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Hold” and a consensus price target of $100.80.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 124.86 on Thursday. The stock’s market capitalization is $11.45 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $125.96. The firm has a 50-day moving average of $98.08 and a 200 day moving average of $76.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.05) earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total value of $10,664,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the completion of the transaction, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What are top analysts saying about Alnylam Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit